Halozyme Appoints Former CFO David Ramsay as Interim Chief Financial Officer

summarizeSummary

Halozyme Therapeutics appointed David Ramsay, a former CFO, as Interim Chief Financial Officer, providing experienced leadership during the search for a permanent replacement.

check_boxKey Events

• Interim CFO Appointed

  David Ramsay has been appointed Interim Chief Financial Officer, effective March 23, 2026, while the company conducts an active search for a permanent CFO.

• Experienced Leader Returns

  Mr. Ramsay previously served as Halozyme's CFO from 2003-2009 and 2013-2015, bringing deep institutional knowledge and financial expertise to the role.

• Compensation Package Detailed

  Mr. Ramsay will receive a monthly salary of $50,000 and an initial equity grant of 10,000 restricted stock units (RSUs), with potential for an additional 2,500 RSUs if his interim service extends beyond July 1, 2026.

auto_awesomeAnalysis

Halozyme Therapeutics has appointed David Ramsay, a former CFO of the company, as its Interim Chief Financial Officer. This move provides critical stability and continuity in financial leadership during the ongoing search for a permanent CFO. Mr. Ramsay's extensive prior experience with Halozyme, including guiding the company through significant growth, is a positive signal, ensuring that financial operations remain in capable hands following recent positive news regarding FDA approvals and ongoing strategic initiatives.